Source: Instrument House, it may not be reproduced without authorization, and it can only be reproduced after 24 hours
On October 8, the major A-share indices all achieved sharp gains. The Shanghai Composite Index closed up 4.59%, the Shenzhen Component Index rose 9.17%, and the ChiNext Index surged 17.25%. In addition, the BSE 50 Index and the STAR 50 Index also recorded gains of 24.71% and 17.38%, respectively. The full-day turnover was close to 3.5 trillion yuan, once again refreshing the historical record.
Among them, medical device stocks rose collectively on October 8. As of 9:26 on the same day, the medical device sector index was reported at 924.724 points, an increase of 16%, with a turnover of 1.937 billion yuan and a turnover rate of 0.19%.
As of the close of trading on October 8, many stocks in the sector rose greatly, and the top 5 stocks with the largest gains were: Boxun Biotechnology reported 19.23 yuan, up 29.58%; Zhongke Meiling reported 12.8 yuan, up 22.37%; Chenguang Medical reported 10.95 yuan, up 20.07%; Yangpu Medical reported 7.91 yuan, up 20.03%; Bairen Medical reported 139.18 yuan, up 20%.
Among its heavy stocks, Mindray Medical reported 324.5 yuan, up 10.75%; United Imaging Medical reported 139.54 yuan, up 9.02%; Aimeike reported 282.72 yuan, up 20.00%; Yuyue Medical reported 38.28 yuan, flat, and New Industry reported 87.80 yuan, up 7.13%; Huitai Medical reported 439.00 yuan, up 7.23%; HP Medical reported 15.36 yuan, up 16.63%.
01
The medical equipment sector rose collectively
The highest increase was 29.58%
In the medical device sector, the top 10 stocks with the largest gains are Boxun Biotechnology, Zhongke Meiling, Chenguang Medical, Yangpu Medical, Bairen Medical, Yirui Technology, Aidite, TINAVI, Yingke Medical and Lude Medical.
Bairen Medical rose 20%
Among them, Bairen Medical's closing stock price on October 8 was 139.18 yuan, the share price rose 23.2 yuan, an increase of 20%, and the company's total market value rose to 19.123 billion yuan.
According to the data, Bairen Medical was established in 2005 and is a high-tech enterprise focusing on the R&D and production of animal-derived implantable interventional medical devices, which are mainly used in heart valve replacement and repair, congenital heart disease implant interventional treatment and surgical soft tissue repair.
Bairen Medical's 2024 semi-annual report shows that from January to June 2024, the company achieved a total operating income of 191 million yuan, a year-on-year increase of 13.74%, and a net profit of 35.1907 million, a year-on-year decrease of 20.42%.
Yirui Technology has the highest share price among the top 10 gainers
It is worth mentioning that among the top ten stocks, Yirui Technology's share price was the highest, with a closing price of 152.21 yuan on October 8, a share price increase of 25.37 yuan, an increase of 20%, and the company's total market value of 21.734 billion yuan.
Yirui Technology is a leading domestic enterprise of X-ray detectors, and is moving towards the world's leading supplier of X-ray products and solutions. Through more than ten years of technology accumulation, the company has gradually formed a leading edge and gradually formed import substitution by relying on independent research and development. It has four sensor technologies: amorphous silicon, IGZO, CMOS and flexible substrates, and can provide hardware, software and complete integrated solutions for the image chain.
With the continuous development of the sinking of domestic medical imaging equipment, the demand for upstream parts of domestic equipment manufacturers is expected to continue to increase.
At present, the company has successfully broken the monopoly of foreign technology in digital X-ray detectors and high-voltage generators, and is accelerating the R&D and design and mass production capacity building of tube products, and gradually moving towards "a variety of X-ray core components and comprehensive solution providers".
October 8 Medical Device Sector Gainers List (Top 20)
02
The rally of heavy medical equipment stocks attracted attention
Among the heavy stocks of medical devices, as of the close of trading on October 8, Mindray Medical rose 10.75%, United Imaging Medical rose 9.02%, Aimeike rose 20.00%, Yuyue Medical was the same as the previous trading day, New Industry rose 7.13%, Huitai Medical rose 7.23%, and HP Medical rose 16.63%.
Mindray Medical up 10.75%
As a leading enterprise in the medical device industry, Mindray has strong strength and competitive advantages in R&D, production and sales, and its products cover many medical device fields, such as monitors, ultrasound diagnostic equipment, etc., and have a high reputation and market share in domestic and foreign markets.
In fact, before the National Day, the market rose, and more than 60 IVD companies all rose, with a total increase of more than 200 billion. From September 26 to 30, in just three trading days, 63 IVD stocks in the A-share IVD sector rose across the board, and none of them fell.
The first place in market value growth is Mindray, which rose nearly 70 billion in three trading days and returned to 350 billion. The average daily increase is about 23 billion, which is equivalent to the market value of an IVD leader.
On October 8, Mindray Medical closed at 324.5 yuan, and its share price rose 31.5 yuan, or 10.75%, with a total market value of 393.4 billion yuan.
United Imaging Healthcare up 9.02%
United Imaging Healthcare is a leading manufacturer of high-end medical imaging equipment, committed to providing advanced imaging diagnostic solutions to medical institutions around the world. The company's self-developed products cover X-ray, magnetic resonance, ultrasound and other fields, with technological innovation as the core, to promote the continuous progress of medical imaging technology, and bring patients a more accurate and safer diagnostic experience.
On October 8, United Imaging Medical closed at 139.54 yuan, and its share price rose 11.54 yuan, or 9.02%, with a total market value of 115 billion yuan.
Aimeike up 20%
In August this year, Aimeike, a leading medical beauty company, released its 2024 semi-annual report. According to the report, its operating income was 1.657 billion yuan, a year-on-year increase of 13.53%; The net profit attributable to the parent company was 1.121 billion yuan, a year-on-year increase of 16.35%. It should be pointed out that although the profit has achieved double growth, compared with the same period in the past three years, its performance growth has slowed down significantly.
From the perspective of the secondary market, at that time, Aimeike's share price had fallen by 60% from the highest point last year, and its market value also shrank to 42.7 billion on August 23, which has evaporated nearly 140 billion from the peak market value of 180 billion. The market is red this time, which also pulls up the share price of Aimeike.
As of October 8, Aimeike's share price closed at 282.72 yuan, the share price rose 47.12 yuan, an increase of 20%, and the company's total market value was 85.505 billion yuan, doubling from the financial report released in August.
03
Medical device giants set off a merger and acquisition frenzy
The three major tracks have become investment sweets
At present, the pharmaceutical and biological industry has become the focus of the capital market in the third quarter, and institutions have investigated a total of 277 listed companies, among which medical devices and chemical pharmaceuticals are particularly popular. Previously, the three major medical device giants, Mindray Medical, United Imaging Healthcare and Xinmai Medical, were surveyed by 667, 500 and 300 institutions respectively, showing that investors are highly concerned about this field.
With the intensification of competition in the medical device industry, leading companies have consolidated their market positions through mergers and acquisitions. Mindray said that in recent years, the company has accelerated the pace of mergers and acquisitions, mainly from the strategic direction of strengthening its main business, exploring new businesses and expanding overseas markets. United Imaging Medical also revealed in the institutional survey that it will pay close attention to core technologies that can improve product performance or improve cost structure, as well as mergers and acquisitions opportunities that can expand product lines or bring new growth points. These M&A activities not only help companies quickly integrate cutting-edge technologies on a global scale, but also accelerate their overseas market layout and lay a solid foundation for future development.
In the wave of globalization, Chinese medical device companies are accelerating the layout of overseas markets. Mindray revealed that the international market is growing faster than the domestic market, especially in developing countries and the European market. United Imaging Healthcare's products have served more than 12,600 medical and scientific research institutions around the world, covering more than 70 countries and regions, and its international market revenue increased by about 30% year-on-year in the first half of the year. The company has sold its products to 155 countries and regions, and has set up 11 overseas subsidiaries. These data fully prove that the internationalization strategy is becoming a magic weapon for Chinese medical device companies, and also provides investors with a new investment direction.
However, it should be pointed out that although the medical device industry has a bright future, investors still need to be wary of potential risks. On the one hand, the pharmaceutical and biological index rose by 11.15% at the end of September, showing the market's enthusiasm for the sector. According to the analysis of Everbright Securities, the overall PE level of the pharmaceutical sector is still at a low level, and there is room for repair. On the other hand, factors such as intensified industry competition, high R&D investment, and changes in regulatory policies may affect business operations. Therefore, investors should pay attention to factors such as low valuation, overseas potential, and rigid demand in hospitals, and at the same time pay close attention to high-dividend OTC stocks, state-owned enterprise reform expectations, innovative drugs and analogues going overseas and other subdivisions, so as to grasp the investment opportunities in the medical device industry.
04
The industry revealed that medical equipment stocks rose collectively
In the face of the collective rise in the stock price of medical devices, there is a view that the current government attaches great importance to the development of the medical device industry and has continuously introduced a series of support policies, such as encouraging innovation, increasing R&D investment support, and standardizing operation and management. These policies are conducive to improving the quality management level of medical device operation, promoting the healthy and rapid development of the industry, enhancing the market's confidence in medical device companies, attracting investors to buy related stocks, and promoting the rise of stock prices.
At the same time, the state promotes large-scale equipment renewal and increases investment in the medical and health field, which means that the procurement demand for medical devices by medical institutions will increase significantly, bringing a broad market space for medical device companies, thereby stimulating the rise of stocks.
In addition, in order to promote the development of the medical device industry, some regions have introduced policies such as tax incentives and industrial park support, which have reduced the operating costs of enterprises and improved the profitability of enterprises, which will also have a positive impact on related stocks.
From the perspective of technological innovation and breakthroughs on the enterprise side, the medical device industry is a technology-intensive industry, and enterprises continue to increase R&D investment and have achieved a series of innovative results. The introduction of new technologies and products has improved the core competitiveness of enterprises and brought new profit growth points to enterprises.
At the same time, with the continuous improvement of the technical level of domestic medical device enterprises, they have been able to compete with international giants in some fields. With the support of national policies, the process of domestic substitution has accelerated, and the share of domestic enterprises in the domestic market has gradually increased, and they are also actively expanding overseas markets, which has brought new opportunities for the development of enterprises and promoted the rise of related stocks.
Then, with the gradual implementation of a series of favorable policies, coupled with the release of previous deferred demand, it is expected that the prosperity of the overall device sector will be fully boosted in the future. The home of equipment will also continue to bring you the latest market trends.